The present disclosure is directed to compositions comprising Lactobacillus plantarum CECT 7484, Lactobacillus plantarum CECT 7485, and Pediococcus acidilactici CECT 7483 or a mutant or variant thereof. This composition is useful in the treatment of gastrointestinal diseases or conditions such as ...
(Lactiplantibacillus plantarumCECT 7484 and 7485 andPediococcus acidilacticiCECT 7483). We evaluated the impact of a 30-day treatment both on FI subjects and healthy volunteers. The gastrointestinal symptoms and fecal volatile metabolome were evaluated. A statistically significant improvement of symptoms...